Posts Tagged ‘biotech’

Now that December is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in November – they’re ranked in order of popularity, with number one being the most viewed piece. 10 Headlines That Suggest Donald Trump […]

As one of Salesforce’s strategic partners, I’m glad to share the success Eli Lilly is having with the Salesforce platform. According to a press release that was issued by Salesforce, the pharmaceutical company has launched 50+ internal and external applications over the last two years. TrialGuide is one example. The website, which is naturally mobile-friendly, […]

This year’s presidential election invoked serious fear in the pharmaceutical industry, with the cost of drugs taking center stage for a good portion of some candidates’ campaigns. While what candidates say they’ll do could very well be different than what they’ll try to do, their words and records are enough to push pundits, investors, and […]

Bayer recently launched its first Facebook ad. The ad also happens to be the first time Facebook has allowed a company to put important safety information (ISI) in a scrolling format, something that pharmaceutical companies have long been able to do in banner ads. In addition, the social media giant is also enabling drug companies […]

Now that November is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in October – they’re ranked in order of popularity, with number one being the most viewed piece. Pharma Reps Continue To Struggle […]

A new study found that pharmaceutical sales reps are finding it more difficult to meet with physicians in person. Compared to 2008, when nearly 80% of physicians agreed to meet with most reps, now: 44% of physicians are “accessible,” meaning they meet with more than 70% of sales reps who pursue them 38% of physicians […]

Innovative mobile technologies are continuously being introduced, and savvy life sciences organizations are taking note. Many of these technologies have the potential to drastically reduce the time and cost of clinical trials, from subject recruitment to data collection, not to mention likely create a boost in patient engagement. Examples of using digital technologies in clinical […]

A recent conversation with a prospective client of ours prompted me to write this post. The client is looking at ways to improve the adoption rate of one of its products by a specific population because, for a variety of reasons, adoption by that segment has been slower than others. The solution to challenges like […]

It seems every company in every industry is talking about “going digital.” But, what does that really mean? At its heart, going digital is really just about relationships: relationships with customers, partners, team members, and the world at large. Since the introduction of mobile and digital technology, the ways in which we interact with others […]

In the European Union, the use of E2B(R3), along with IDMP, is in legislation, so not complying by the deadline could have legal repercussions. Non-compliance with the FDA and MHLW’s requirements could also bring unwanted scrutiny. More importantly, if an organization does not comply by the deadlines, they will not be able to send ICSRs […]

Yes, some validated systems can comply with E2B(R3). With respect to Oracle Argus Safety, the current version, 8.0.1, is able to comply with E2B(R3), Electronic Vaccine Adverse Event Reporting System (eVAERS), and Electronic Medical Device Reporting (eMDR) reporting requirements. If a company is simply looking to meet E2B(R3) requirements, we advise waiting to upgrade until […]

Now that August is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in July – they’re ranked in order of popularity, with number one being the most viewed piece. When Do Companies Have To […]